Table 1.
Patient Baseline Demographic and Clinical Characteristics
| Characteristic | YS110 6 mg/kg (N = 31) |
Nivolumab Treatment History |
|
|---|---|---|---|
| Previously Treated (n = 12, 38.7%) Group A | Untreated (n = 19, 61.3%) Group B | ||
| Age (y), median (range) | 68 (55–81) | 67 (55–81) | 68 (57–75) |
| Sex, n (%) | |||
| Male | 28 (90.3) | 10 (83.3) | 18 (94.7) |
| Female | 3 (9.7) | 2 (16.7) | 1 (5.3) |
| Tumor histology, n (%) | |||
| Epithelioid | 26 (83.9) | 10 (83.3) | 16 (84.2) |
| Sarcomatoid | 2 (6.5) | 1 (8.3) | 1 (5.3) |
| Biphasic | 3 (9.7) | 1 (8.3) | 2 (10.5) |
| CD26 expression in tumor tissue, % | |||
| Mean ± SD | 71.3 ± 31.44 | 62.9 ± 35.96 | 76.6 ± 27.94 |
| <20%, n (%) | 3 (9.7) | 2 (16.7) | 1 (5.3) |
| ≥20%, n (%) | 28 (90.3) | 10 (83.3) | 18 (94.7) |
| ECOG performance status, n (%) | |||
| 0 | 12 (38.7) | 5 (41.7) | 7 (36.8) |
| 1 | 19 (61.3) | 7 (58.3) | 12 (63.2) |
| Tumor stage (IMIG TMN), n (%) | |||
| II | 3 (9.7) | 0 | 3 (15.8) |
| III | 8 (25.8) | 3 (25.0) | 5 (26.3) |
| IV | 20 (64.5) | 9 (75.0) | 11 (57.9) |
ECOG, Eastern Cooperative Oncology Group; IMIG, International Mesothelioma Interest Group; TMN, tumor-node metastasis.